Thyroid cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• NTRK 2
• PD-1 5
• RAS 1
• ERK 0
• MEK 1
• PSMA 1
• ALK 1
• EGFR 3
• VEGF 2
• PD-L1 0
• JAK 0
• KRAS 1
• CTNNB1 0
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CDKN2A 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• GPX4 0
• HMGB1 0
• IDH 0

18 of 18+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €2,497,392· until Dec 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Chemotherapy-induced Alopecia - Relief Managed by Engineered Silk (CARMESilk)

  Friedrich-Schiller-Universität Jena· Jena, Germany· EU contribution €401,232· until Sept 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Croatia· EU contribution €4,937,275· until Dec 2028· 2 countries

3 of 3 running projects, newest first. Listed amounts together: €7.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

  NCT04544111· Memorial Sloan Kettering Cancer Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• Beyond traditional biopsy: integrating liquid biopsy, molecular panels, and advanced imaging techniques in thyroid cancer management.

  Endokrynol Pol, Sept 2026

• Comprehensive Review of Extracellular Vesicles in Thyroid Cancer: From Methodological Approaches to Biological Functions and Clinical Applications.

  Int J Mol Sci, Aug 2026

• The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches.

  Expert Rev Anticancer Ther, Jul 2026

• Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

  Endocrine, Jun 2026

• Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique.

  Clin Cancer Res, Apr 2026

• Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.

  Front Endocrinol (Lausanne), Mar 2026

• Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease.

  Thyroid, Jan 2026

• Tumor-informed liquid biopsy for monitoring thyroid cancer: a proof-of-concept study.

  Eur Thyroid J, Jan 2026

• The diagnostic and prognostic potential of extracellular vesicles as biomarkers for thyroid cancer: a systematic review.

  J Mol Med (Berl), Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.